SIGMAR1 and cardiac hypertrophy: A number of studies have shown that stimulation of Sigmar1 using its agonists (e.g., dehydroepiandrosterone and fluvoxamine) elicit protective effects against PO-induced cardiac hypertrophy in ovariectomized rats and TAC-induced cardiac hypertrophy in mice (Bhuiyan and Fukunaga, 2009; Bhuiyan et al., 2010; Tagashira et al., 2010).